COVID BREAKTHROUGH: ANCIENT EGYPTIAN TREATMENT COULD REDUCE RISK OF DEATH BY 50%
Researchers claim that an ancient Egyptian gout treatment could reduce the risk of death from COVID-19 by 50%. A new study published in the European Journal of Internal Medicine found that a drug derived from the saffron plant has promising properties. Gout, a type of arthritis that causes severe joint pain, has long been treated with the drug colchicine.
The drug, according to researchers from the Hebrew University of Jerusalem and Hadassah Medical School, has the potential to treat people with severe cases of Covid and reduce mortality rates by up to 50%.
Colchicine is one of the few medicines from thousands of years ago that has made it to the modern era and is still in use. Its medicinal properties were known by the Ancient Egyptians as early as 1500 BC, according to the Ebers Papyrus. Because of its ability to treat swelling and pain, the drug’s properties were also well known to the Ancient Greeks and the Byzantine Empire.
Colchicine is currently being researched by researchers all over the world to see if it can help people who are infected with the COVID-19 coronavirus. Moreover, various studies have shown a “clear benefit” from its use, according to Professor Ami Schattner of the Hebrew University.
Colchicine’s potential to treat Covid was discovered after a 20-year review of clinical data and studies. This includes four controlled studies involving approximately 6,000 Covid patients, each of which showed “significant improvement in severe coronavirus indices and, most importantly, a 50% reduction in mortality compared to those who were not treated with colchicine,” according to Professor Schattner.
Colchicine is a promising breakthrough in the fight against the pandemic because it is inexpensive to produce and widely available. South Africa, Canada, Greece, Spain, and Brazil have all tested the drug’s effectiveness against Covid.
Professor Schattner, on the other hand, cautioned that the preliminary findings are insufficient to begin mass-distribution of the drug:
“Even though preliminary data on the effect of colchicine on coronavirus patients is very promising,” he said, “more patients in randomized controlled trials are needed.”
“However, that would not stop me from using the drug in patients who are already at high risk of developing cancer.”
Editors Notes:
THIS ARTCILE BY PASCAL NALAT, FIRST APPEARED IN BRINKWIRE ON 17TH DECEMBER 2021
Hadassah UK proudly support Hadassah Hospital’s mission of peaceful coexistence, dedication to saving lives today, and finding medical solutions for a world of tomorrow.
